Renal function and outcomes in acute coronary syndrome: impact of clopidogrel

Introduction Patients with renal dysfunction are more prone to bleeding when receiving antithrombotic drugs. The aim of the study was to assess the impact of clopidogrel on safety and efficacy in patients with renal dysfunction in non-ST elevation acute coronary syndromes. Methods and results Patients in the Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) trial were analysed to assess the relationship of chronic kidney disease to cardiovascular outcomes. Renal function was estimated by the glomerular filtration rate computed from the baseline serum creatinine measurements in 12253 (97.5%) patients enrolled in the trial. Patients were grouped into tertiles of glomerular filtration rate. The primary outcome (cardiovascular death, myocardial infarction, stroke combined) occurred more frequently in the lowest glomerular filtration rate tertile. The bleeding risk was also significantly increased in patients in this tertile, compared with the other two. The beneficial effect of adding clopidogrel to standard treatment in non-ST elevation acute coronary syndrome was observed in all three tertiles of renal function {(lower third relative risk (RR) = 0.89 [95% confidence interval (CI) 0.76–1.05]; medium third RR = 0.68 (95% CI 0.56–0.84); upper third RR = 0.74 (95% CI 0.60–0.93) (P for heterogeneity = 0.11)}. Clopidogrel treatment significantly increased the risk of minor bleeding in all tertiles of renal function. The risk of major or life-threatening bleeding increased moderately with the addition of clopidogrel to standard treatment [lower third RR = 1.12 (95% CI 0.83–1.51); medium third RR = 1.4 (95% CI 0.97–2.02); upper third RR = 1.83 (95% CI 1.23–2.73)], but this did not appear to be greatest in those with the lowest renal function. Conclusions Even mild chronic kidney disease worsens the prognosis in patients with non-ST elevation acute coronary syndromes. Clopidogrel was beneficial and safe in patients with and without chronic kidney disease.

[1]  S. Yusuf,et al.  Acute coronary syndromes without ST segment elevation , 2007, BMJ : British Medical Journal.

[2]  E. Antman,et al.  Association of glomerular filtration rate on presentation with subsequent mortality in non-ST-segment elevation acute coronary syndrome; observations in 13,307 patients in five TIMI trials. , 2004, European heart journal.

[3]  Á. Avezum,et al.  A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. , 2004, Journal of the American Medical Association (JAMA).

[4]  T. Pinkau,et al.  How does minor renal dysfunction influence cardiovascular risk and the management of cardiovascular disease? , 2004, Journal of the American Society of Nephrology : JASN.

[5]  E. Antman,et al.  Association of creatinine and creatinine clearance on presentation in acute myocardial infarction with subsequent mortality. , 2003, Journal of the American College of Cardiology.

[6]  Deepak L. Bhatt,et al.  Bivalirudin provides increasing benefit with decreasing renal function: a meta-analysis of randomized trials. , 2003, The American journal of cardiology.

[7]  S. Yusuf,et al.  Effects of Aspirin Dose When Used Alone or in Combination With Clopidogrel in Patients With Acute Coronary Syndromes: Observations From the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Study , 2003, Circulation.

[8]  S. Borzak,et al.  Analysis of long-term survival after revascularization in patients with chronic kidney disease presenting with acute coronary syndromes. , 2003, The American journal of cardiology.

[9]  J. Gore,et al.  Creatinine clearance and adverse hospital outcomes in patients with acute coronary syndromes: findings from the global registry of acute coronary events (GRACE) , 2003, Heart.

[10]  Pascal J. Goldschmidt-Clermont,et al.  Aging, Progenitor Cell Exhaustion, and Atherosclerosis , 2003, Circulation.

[11]  P. McCullough.  Why is chronic kidney disease the "spoiler" for cardiovascular outcomes? , 2003, Journal of the American College of Cardiology.

[12]  E. Braunwald,et al.  Effects of renal insufficiency on early invasive management in patients with acute coronary syndromes (The TACTICS-TIMI 18 Trial). , 2002, The American journal of cardiology.

[13]  Eric J Topol,et al.  Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. , 2002, JAMA.

[14]  A. Jaffe,et al.  Acute Myocardial Infarction and Renal Dysfunction: A High-Risk Combination , 2002, Annals of Internal Medicine.

[15]  M. Mcclellan,et al.  Association of Renal Insufficiency with Treatment and Outcomes after Myocardial Infarction in Elderly Patients , 2002, Annals of Internal Medicine.

[16]  R. Califf,et al.  Prognostic Implications of Abnormalities in Renal Function in Patients With Acute Coronary Syndromes , 2002, Circulation.

[17]  S. Snapinn,et al.  Benefits and Safety of Tirofiban Among Acute Coronary Syndrome Patients With Mild to Moderate Renal Insufficiency: Results From the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Trial , 2002, Circulation.

[18]  C. Vassanelli,et al.  [Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban]. , 2001, Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology.

[19]  S. Yusuf,et al.  Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. , 2001, The New England journal of medicine.

[20]  E. Braunwald,et al.  Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. , 2001, The New England journal of medicine.

[21]  S. Yusuf,et al.  Renal Insufficiency as a Predictor of Cardiovascular Outcomes and the Impact of Ramipril: The HOPE Randomized Trial , 2001, Annals of Internal Medicine.

[22]  S. Yusuf,et al.  The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme; rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease. , 2000, European heart journal.

[23]  J. Yee,et al.  Risks associated with renal dysfunction in patients in the coronary care unit. , 2000, Journal of the American College of Cardiology.

[24]  E W Steyerberg,et al.  Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients. The PURSUIT Investigators. , 2000, Circulation.

[25]  A. Levey,et al.  A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation , 1999, Annals of Internal Medicine.

[26]  C. Bagnis,et al.  Clopidogrel Activities in Patients with Renal Function Impairment , 1998, Clinical drug investigation.